Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,842 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Morizane C, Mizuno N, Ikeda M, Ueno M, Furuse J. Kobayashi S, et al. Among authors: otsuka t. Cancer Sci. 2018 Aug;109(8):2549-2557. doi: 10.1111/cas.13656. Epub 2018 Jun 27. Cancer Sci. 2018. PMID: 29856900 Free PMC article.
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Koga F, Kawaguchi Y, Shimokawa M, Murayama K, Nakashita S, Oza N, Ureshino N, Takahashi H, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Shirakawa T, Otsuka T, Mitsugi K. Koga F, et al. Among authors: otsuka t. J Geriatr Oncol. 2022 Jan;13(1):82-87. doi: 10.1016/j.jgo.2021.06.011. Epub 2021 Jun 29. J Geriatr Oncol. 2022. PMID: 34215525
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Arima S, Kawahira M, Shimokawa M, Ido A, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Mitsugi K, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Otsuka T. Arima S, et al. Among authors: otsuka t. Pancreas. 2021 Aug 1;50(7):957-964. doi: 10.1097/MPA.0000000000001859. Pancreas. 2021. PMID: 34347735
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Shibuki T, Mizuta T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T, Otsuka T. Shibuki T, et al. Among authors: otsuka t. BMC Cancer. 2022 Jan 3;22(1):19. doi: 10.1186/s12885-021-09139-y. BMC Cancer. 2022. PMID: 34980029 Free PMC article.
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Ide Y, Otsuka T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Shinohara Y, Ueno S, Taguchi H, Honda T, Shibuki T, Nio K, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Ide Y, et al. Among authors: otsuka t. Anticancer Res. 2023 Apr;43(4):1817-1826. doi: 10.21873/anticanres.16335. Anticancer Res. 2023. PMID: 36974805
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Fukahori M, Okabe Y, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Makiyama A, Taguchi H, Honda T, Ushijima T, Miwa K, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Fukahori M, et al. Among authors: otsuka t. Sci Rep. 2023 Nov 8;13(1):19399. doi: 10.1038/s41598-023-46924-0. Sci Rep. 2023. PMID: 37938630 Free PMC article.
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Kodama T, Imajima T, Shimokawa M, Otsuka T, Kawahira M, Nakazawa J, Hori T, Shibuki T, Arima S, Ido A, Miwa K, Okabe Y, Koga F, Ueda Y, Kubotsu Y, Shimokawa H, Takeshita S, Nishikawa K, Komori A, Otsu S, Hosokawa A, Sakai T, Sakai K, Oda H, Kawahira M, Arita S, Honda T, Taguchi H, Tsuneyoshi K, Kawaguchi Y, Fujita T, Sakae T, Shirakawa T, Mizuta T, Mitsugi K. Kodama T, et al. Among authors: otsuka t. Sci Rep. 2024 May 30;14(1):12422. doi: 10.1038/s41598-024-63172-y. Sci Rep. 2024. PMID: 38816500 Free PMC article.
1,842 results